If you're interested in Rogers Corporation (NYSE:ROG), then you might want to consider its beta (a measure of share...

Rogers Corporation (NYSE:ROG) today announced financial results for the first quarter of 2020.

Rogers Corp. (ROG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rogers (NYSE:ROG) shareholders are no doubt pleased to see that the share price has bounced 33% in the last month...

The Swiss drug maker said the Elecsys Anti-Sars-CoV-2 immunoassay is an in-vitro test to detect antibodies and assess the body’s immune reaction to Sars-CoV-2, better known as Covid-19, using human serum and plasma from a blood sample.

Rogers Corporation (NYSE:ROG), which is in the electronic business, and is based in United States, led the NYSE...

Roche Holding AG said Wednesday that sales rose in the first quarter and backed its full-year outlook.

Today we are going to look at Rogers Corporation (NYSE:ROG) to see whether it might be an attractive investment...

The National Institute of Allergy and Infectious Diseases (NIAID) said Friday it is testing Gilead Sciences Inc.'s remdesivir in combination with Eli Lilly & Co.'s rheumatoid arthritis drug Olumiant in COVID-19 patients as part of the next phase of the randomized, controlled clinical trial that led to the authorization of remdesivir. This study will enroll 1,000 people at more than 100 sites in the U.S. and abroad, to "examine if adding an anti-inflammatory agent to the remdesivir regimen can provide additional benefit for patients," NIAID director Dr. Anthony Fauci said in a statement. The topline results from the remdesivir trial helped make up the basis of the Food and Drug Administration's (FDA) emergency use authorization for the drug last week. A number of medicines that have been previously approved by the FDA to treat rheumatoid arthritis have been proposed as possible COVID-19 treatments, including Regeneron Pharmaceuticals Inc. and Sanofi's Kevzara and Roche Holding AG's Actemra. Olumiant, which was developed by Incyte Corp. and is licensed to Lilly, brought in $427 million in sales in 2019 for the Indianapolis-based drugmaker. Only two types of therapies - remdesivir and hydroxycholorquine and chlorquine - are authorized by the FDA as COVID-19 treatments. Year-to-date, Gilead's stock has gained 18.6%, while shares of Lilly are up 16.6%. The S&P 500 is down 10.8%.

Shares of Roche Holding AG gained 2.4% in premarket trading on Thursday after the drugmaker said it is testing a combination of its rheumatoid arthritis drug Actemra with Gilead Sciences Inc.'s remdesivir in hospitalized COVID-19 patients. Gilead's stock was down 0.4%. Roche has previously announced it is studying Actemra in 450 hospitalized COVID-19 patients participating in a randomized, double-blind, placebo-controlled late-stage trial; results from that trial are expected "this summer," Roche said. The new Phase 3, randomized, double-blind, multicenter study will test Actemra and remdesivir against placebo and remdesivir in about 450 patients hospitalized with severe COVID-19 pneumonia. Trial sites are in Canada, Europe, and the U.S. The Food and Drug Administration granted an emergency use authorization to remdesivir on May 1 as a treatment for some severely ill COVID-19 patients. The experimental drug has not been approved as a treatment for the disease caused by the coronavirus. Since the start of the year, Roche's stock is up 8.2%, Gilead's stock has gained 15.2%, and the S&P 500 has declined 6.0%.

Shares of Gilead Sciences Inc. gained 0.4% in trading on Monday after BMO Capital Markets downgraded the stock to market perform from outperform. Analysts there believe that despite [l: investor excitement about remdesivir, an experimental drug being tested as a treatment for COVID-19 patients, they "no longer see favorable risk/reward in shares given continued uncertainty around the remdesivir commercial opportunity." They wrote that progression of vaccines in development, which would prevent infection with the virus, raise questions about the durability of a post-infection treatment, noting that Roche AG's Tamiflu flu treatment generated more than $3 billion in revenue in 2009 during the H1N1 pandemic but sales of that drug brought in an average of $670 million annually after that. Year-to-date, Gilead's stock is up 29.6%, while the S&P 500 is down 11.0%.

Q1 2020 Rogers Corp Earnings Call

Here's a sneak peek into how five electronics stocks might fare in their upcoming quarterly results, slated to release on Apr 30.

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

Rogers Corp. (ROG) delivered earnings and revenue surprises of 12.20% and 4.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

ROG earnings call for the period ending March 31, 2020.

By Chuck Royce, Lauren Romeo and Steven McBoyle Continue reading...

Rogers Corporation (NYSE:ROG) plans to announce first quarter 2020 results on April 30 after market close, which will be followed by a conference call at 5:00 pm ET. The call will be hosted by Bruce Hoechner, President and CEO, who will be joined by Mike Ludwig, SVP and CFO, and Bob Daigle, SVP and CTO.

Shares of Roche Holding AG are down 3% in trading on Monday after the drugmaker said it had received regulatory approval to begin a late-stage clinical trial examining the safety and effectiveness of Actemra, its rheumatoid arthritis treatment, in hospitalized patients with COVID-19 pneumonia. The randomized, double-blind, placebo-controlled Phase 3 clinical trial will be conducted in partnership with the Biomedical Advanced Research and Development Authority. Actemra was first approved by the Food and Drug Administration in 2010; however, it has not been approved by the regulator for a COVID-19 indication. Roche also said it will provide 10,000 vials of the drug to the U.S. Strategic National Stockpile for potential future use. Roche's stock is down 11% year-to-date, while the S&P 500 has tumbled 28%.

The Food and Drug Administration (FDA) on Monday changed its emergency-use policy for antibody tests, saying that manufacturers now have to seek regulatory authorization. The tests identify COVID-19 antibodies, which indicate a past infection with the novel coronavirus and are believed to provide some level of immunity to future infections; some experts say that widespread antibody testing is needed to reopen the economy. The FDA had announced on March 16 that antibody tests could be performed in some labs without an emergency use authorization (EUA), which is a type of regulatory OK granted during the pandemic. It is not an FDA approval. The makers of more than 200 tests have sought an EUA, and at least 12 have been granted one, including Abbott Laboratories Inc. and Roche Holding AG . But concerns about the quality and marketing claims for some tests that have not received an EUA created concern at the FDA. "The careful balancing of risks and benefits has shifted from where it was in mid-March," the regulator said. Test developers must now submit an EUA request with validation data within 10 days of an FDA notification, and these developers will follow a different submission template than the labs that are also developing antibody tests for authorization. "Flexibility never meant we would allow fraud," the FDA said Monday. "We, unfortunately, see unscrupulous actors marketing fraudulent test kits and using the pandemic as an opportunity to take advantage of Americans' anxiety." This includes claiming the tests are FDA approved or authorized, that they can be conducted at home, or can be used to diagnose COVID-19, according to the FDA. The regulator noted that all forms of antibody tests can produce false results, based on their "inherent limitations," and in some cases at least two antibody tests may need to be performed for one patient.